Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)

Yukinori Ozaki, Shohei Koyama, Satoshi Morita, Minoru Miyashita, Emi Tokuda, Tatsunori Shimoi, Megumi Fukuoka, Hiroko Masuda, Yuko Takano, Nobuhiro Shibata, Tetsuhiro Yoshinami, Akari Murakami, Kentaro Tamaki, Hiroshi Ishiguro, Shigehira Saji, Asako Miwa, Junko Matsunaga, Yue Zheng, Hiroyoshi Nishikawa, Norikazu Masuda

Open source

DOI: 10.1136/bmjopen-2024-098088
Published: 2026-05
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2024-098088,
  title = {Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)},
  author = {Yukinori Ozaki and Shohei Koyama and Satoshi Morita and Minoru Miyashita and Emi Tokuda and Tatsunori Shimoi and Megumi Fukuoka and Hiroko Masuda and Yuko Takano and Nobuhiro Shibata and Tetsuhiro Yoshinami and Akari Murakami and Kentaro Tamaki and Hiroshi Ishiguro and Shigehira Saji and Asako Miwa and Junko Matsunaga and Yue Zheng and Hiroyoshi Nishikawa and Norikazu Masuda},
  year = {2026},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2024-098088},
  url = {https://doi.org/10.1136/bmjopen-2024-098088}
}

RIS

TY  - JOUR
TI  - Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
AU  - Yukinori Ozaki
AU  - Shohei Koyama
AU  - Satoshi Morita
AU  - Minoru Miyashita
AU  - Emi Tokuda
AU  - Tatsunori Shimoi
AU  - Megumi Fukuoka
AU  - Hiroko Masuda
AU  - Yuko Takano
AU  - Nobuhiro Shibata
AU  - Tetsuhiro Yoshinami
AU  - Akari Murakami
AU  - Kentaro Tamaki
AU  - Hiroshi Ishiguro
AU  - Shigehira Saji
AU  - Asako Miwa
AU  - Junko Matsunaga
AU  - Yue Zheng
AU  - Hiroyoshi Nishikawa
AU  - Norikazu Masuda
PY  - 2026
JO  - BMJ Open
DO  - 10.1136/bmjopen-2024-098088
UR  - https://doi.org/10.1136/bmjopen-2024-098088
ER  -

APA

Ozaki, Y., Koyama, S., Morita, S., Miyashita, M., Tokuda, E., Shimoi, T., Fukuoka, M., Masuda, H., Takano, Y., Shibata, N., Yoshinami, T., Murakami, A., Tamaki, K., Ishiguro, H., Saji, S., Miwa, A., Matsunaga, J., Zheng, Y., Nishikawa, H., & Masuda, N. (2026). Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). BMJ Open. https://doi.org/10.1136/bmjopen-2024-098088

Source records

crossref · retrieved 2026-09-26T15:18:50.792Z